Drug Combination Details
| General Information of the Combination (ID: C77855) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | L-buthionine sulfoximine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Renal cell carcinoma
[ICD-11: 2C90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Activity | GSTK1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Caki-1 | CVCL_0234 | Clear cell renal cell carcinoma | Homo sapiens | ||
| Caki-2 | CVCL_0235 | Renal cell carcinoma | Homo sapiens | |||
| NC65 | Renal cell carcinoma | Homo sapiens | ||||
| Experimental
Result(s) |
BSO sensitizes RCC cells to As2O3-induced apoptosis through the down-regulation of the intracellular GSH redox system. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine. Int J Oncol. 2004 Jun;24(6):1489-97. | |||
